Refractory or relapsed
Web12. máj 2011 · English term or phrase: relapsed or refractory XXX is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory PTCL. El … Web7. apr 2024 · A phase II study of crizotinib in children with refractory or relapsed ALK-mutated neuroblastoma reported an RR of 15%; in stark contrast, far more objective and sustained responses were observed in ALK-fusion-driven refractory or relapsed anaplastic large cell lymphoma (RR 90%) and inflammatory myofibroblastic tumours (RR 86%), …
Refractory or relapsed
Did you know?
Web6. apr 2024 · The study is designed as an international, multicenter, open-label, two-arm, prospective phase III study to compare the treatment of polatuzumab vedotin plus … Web11. mar 2024 · Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely …
WebIn this small study, a short, chemotherapy-free, nonmyelotoxic regimen of vemurafenib plus rituximab was associated with a durable complete response in most patients with … Web27. feb 2008 · 1.1 Rituximab, within its marketing authorisation, in combination with chemotherapy, is recommended as an option for the induction of remission in people with relapsed stage III or IV follicular non-Hodgkin's lymphoma.. 1.2 Rituximab monotherapy as maintenance therapy, within its marketing authorisation, is recommended as an option for …
WebThe goals for treating relapsed or refractory ALL are: 1. Eliminate as much ALL as possible. 2. Get you to remission. This is when the signs and symptoms of ALL decrease or … Web1. apr 2024 · The available therapeutic modalities for relapsed–refractory Multiple myeloma are discussed, highlighting critical factors that guide the therapy selection process and …
Web20. feb 2024 · We review current management strategies for patients with relapsed and refractory germ cell tumors (GCTs), defined as relapsed or persistent disease following at least one line of cisplatin-based chemotherapy. Additionally, we discuss future directions in the management of these patients. Recent Findings
Web6. apr 2024 · Sacituzumab govitecan (SG), an anti-Trop-2 ADC for pretreating relapsed/refractory mTNBC patients, was studied to know the efficacy and safety profile of the drug in mTNBC. Methods: The present review searched MEDLINE (via PubMed), WHO Clinical Trial Registry, Clinical Trials.gov, and Cochrane Central Register of Controlled … tjc topsWeb21. jan 2024 · i Lonial, S, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet … tjc twitter baseballWebMost patients with relapsed/refractory multiple myeloma (RRMM) have been treated with drug combinations including a proteasome inhibitor (PI) and/or an immunomodulatory … tjc us history chapter 14Web2. nov 2024 · Refractory follicular lymphoma refers to cancer that has not responded to initial therapy. Refractory illness is defined as a disease that grows worse or stays the … tjc us history chapter 15Webpred 50 minútami · Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM), leading to unprecedented responses in this patient population. Idecabtagene vicleucel (ide-cel) has been recently approved for treatment of triple-class exposed RRMM. We report real-life … tjc two year degreesWeb7. apr 2024 · A phase II study of crizotinib in children with refractory or relapsed ALK -mutated neuroblastoma reported an RR of 15%; in stark contrast, far more objective and … tjc tutoring centerWebPatients of any age were eligible at first designation of relapse or progression, or first designation of refractory disease, provided organ function requirements were met. … tjc us history chapter 23